Home > Healthcare > Medical Devices > Therapeutic Devices > Platelet Rich Plasma (PRP) Market

Platelet Rich Plasma (PRP) Market Trends

Report ID: GMI10133
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Platelet Rich Plasma Market Trends

The growing cosmetic and aesthetic applications of platelet-rich plasma (PRP) therapy are significantly driving the PRP market.
Platelet-rich plasma (PRP) has become increasingly popular for cosmetic procedures in recent years, with the American Society of Plastic Surgeons reporting a 25% increase in cosmetic PRP use between 2015 and 2019.
PRP is increasingly sought after for its rejuvenation characteristics, providing a non-surgical alternative for various aesthetic treatments. It is widely used for skin revitalization, reducing wrinkles, fine lines, and scars, as well as for hair restoration.
Additionally, the rising demand for minimally invasive cosmetic procedures, driven by consumer desire for youthful appearance and natural results, further propels the market.
Moreover, increasing awareness of PRP's effectiveness in enhancing skin texture and tone, combined with its safety profile and minimal downtime, has led to a surge in its adoption in dermatology and aesthetic clinics, thereby boosting the overall PRP market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global platelet rich plasma industry was valued at USD 479.6 million in 2023 and is anticipated to register 10.6% CAGR between 2024 and 2032 due to the increasing prevalence of sports injuries and orthopedic conditions.

The pure segment in the PRP market accounted for USD 211.1 million, attributed to its extensive application in various medical and aesthetic procedures.

North America platelet rich plasma industry is anticipated to reach USD 395.4 million by 2032, driven by robust healthcare infrastructure, and high adoption rates of regenerative medicine technologies.

Arthrex Inc., APEX Biologix, Celling Biosciences, Inc., DePuy Synthes (Johnson & Johnson), Dr. PRP USA LLC, EmCyte Corporation, Exactech, Inc., Glofinn Oy, Isto Biologics, Juventix Regenerative Medical, LLC., and Regen Lab SA., among others.